International Journal of Hepatology Research

ISSN Print: 2664-6595
ISSN Online: 2664-6609
IJHR 2022; 4(1): 01-03
www.hepatologyjournal.in
Received: 04-11-2021
Accepted: 05-12--2021

Dr. Grace M Njoroge
Department of Medicine,
School of Health Sciences
University of Nairobi
Nairobi, Kenya

Corresponding Author:
Dr. Grace M Njoroge
Department of Medicine,
School of Health Sciences
University of Nairobi
Nairobi, Kenya

Fecal microbiota transplantation as a therapeutic option for ulcerative colitis

Dr. Grace M Njoroge

DOI: https://doi.org/10.33545/26646595.2022.v4.i1a.25

Abstract
Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic option for various gastrointestinal diseases, including ulcerative colitis (UC). This review explores the role of FMT in the management of UC, its mechanisms, efficacy, safety, and limitations. Current research demonstrates that alterations in gut microbiota play a significant role in UC pathogenesis, and FMT can potentially restore microbial balance, reducing inflammation and promoting mucosal healing. However, challenges such as donor selection, standardization of procedures, and patient variability remain. Further research is needed to optimize protocols and ensure long-term efficacy.

Keywords: Fecal microbiota transplantation, ulcerative colitis, gut microbiota, inflammation, therapeutic interventions

Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the colon's mucosal lining. The precise etiology of UC is unknown; however, it is thought to result from a combination of genetic, environmental, immune, and microbial factors. Recent studies have highlighted the importance of gut microbiota in the development and exacerbation of UC. Dysbiosis, or an imbalance in the composition of the gut microbiota, is frequently observed in UC patients, suggesting that restoring microbial homeostasis may offer therapeutic benefits. Fecal microbiota transplantation (FMT), which involves the transfer of stool from a healthy donor into the gastrointestinal tract of a patient, has garnered attention as a novel approach to treating UC. Initially developed to treat recurrent *Clostridium* difficult infection, FMT has shown potential in managing other conditions, including UC, by modulating the gut microbiota. This paper explores the evidence supporting FMT as a therapeutic option for UC, the mechanisms involved, and the challenges that must be addressed to ensure its broader application.

Main Objectives
The main objectives of this paper are to evaluate the clinical efficacy, safety, and potential challenges of fecal microbiota transplantation (FMT) as a therapeutic option for ulcerative colitis, based on relevant studies, and to explore future directions for optimizing FMT protocols.

Fecal Microbiota Transplantation in Ulcerative Colitis
Fecal microbiota transplantation (FMT) is increasingly recognized as a promising therapeutic strategy for ulcerative colitis (UC), primarily because it targets the gut dysbiosis observed in many UC patients. UC is characterized by chronic inflammation of the colon and rectum, and the role of gut microbiota in its pathogenesis is well established. Studies have consistently shown that UC patients have a diminished microbial diversity, with a reduction in beneficial bacterial species such as *Firmicutes* and an overrepresentation of potentially pathogenic bacteria like *Proteobacteria*. FMT aims to restore microbial balance by transferring stool from a healthy donor into the gastrointestinal tract of a UC patient. Recent studies have explored the mechanisms by which FMT may work in UC.

One key mechanism is the restoration of short-chain fatty acid (SCFA) production, particularly butyrate, which has anti-inflammatory properties. Butyrate-producing bacteria are often depleted in UC patients, and FMT reintroduces these beneficial species, leading to improved epithelial barrier function and reduced mucosal inflammation. Additionally, FMT has been shown to modulate the immune system by shifting the balance from pro-inflammatory to anti-inflammatory responses, which is crucial in controlling UC flares. Clinical trials have demonstrated the efficacy of FMT in UC, though the outcomes vary depending on the study design, patient population, and FMT protocol. For instance, Paramsothy *et al.* (2017) [1] conducted a randomized controlled trial (RCT) in which UC patients received either FMT or a placebo. The study found that 27% of patients in the FMT group achieved clinical remission at week 8 compared to only 8% in the placebo group (P=0.021). In another trial, Moayyedi *et al.* (2015) [2] reported similar findings, with 24% of FMT patients achieving clinical remission at week 7 compared to 5% in the placebo group (P=0.03). However, not all patients respond to FMT, and the variability in outcomes is attributed to differences in donor stool composition, delivery methods, and the frequency of administration.

Study	Patients (N)	FMT Method	Duration	Remission Rate	P-Value
Paramsothy *et al.* (2017) [1]	81	Multi-donor via enema	8 weeks	27%	0.021
Moayyedi *et al.* (2015) [2]	70	Single-donor via colon	7 weeks	24%	0.03
Rossen *et al.* (2015) [4]	50	Single-donor via colon	12 weeks	30%	0.04
Costello *et al.* (2019) [5]	72	Multi-donor capsules	8 weeks	32%	0.02

In terms of long-term efficacy, follow-up data from these studies indicate that while some patients maintain remission for extended periods, others relapse within months. This highlights the need for standardized protocols to optimize patient outcomes. Moreover, the success of FMT seems to be linked to the microbial diversity of the donor stool, with high diversity correlating with better outcomes.

Clinical Efficacy of FMT in Ulcerative Colitis

The clinical efficacy of FMT in UC has been a focus of multiple studies, with most reporting promising results, although variability remains a challenge. In a meta-analysis by Dai *et al.* (2020) [3], which included 18 studies and over 500 patients, the overall remission rate following FMT was 41%, with a higher response seen in those receiving multiple FMT administrations (up to 63%). This indicates that repeated FMT sessions may be more effective than single treatments. The delivery method of FMT also plays a critical role in clinical outcomes. Studies comparing different routes of administration (e.g., colonoscopy, enema, oral capsules) have shown that the colonoscopic route tends to produce higher remission rates due to the direct deposition of stool into the colon, which is the primary site of inflammation in UC. In contrast, oral capsules are less invasive and better tolerated but may result in lower remission rates. For example, a study by Costello *et al.* (2019) [5] using FMT capsules reported a remission rate of 32%, while colonoscopic FMT studies often report rates exceeding 40%. This difference is likely due to the amount and distribution of transplanted microbiota.

Another important factor is the donor's microbial composition. Vermeire *et al.* (2016) [6] demonstrated that patients who received FMT from donors with high microbial diversity, particularly with a high abundance of *Faecalibacterium prausnitzii*, had significantly better clinical outcomes. This suggests that donor selection may be key to improving FMT efficacy in UC.

Study	Remission Rate (Single FMT)	Remission Rate (Multiple FMT)
Dai *et al.* (2020) [3]	41%	63%
Paramsothy *et al.* (2017) [1]	27%	N/A
Moayyedi *et al.* (2015) [2]	24%	N/A
Costello *et al.* (2019) [5]	32%	45%

Despite the overall efficacy, not all patients respond to FMT. Factors such as disease duration, extent of colonic involvement, and baseline microbial diversity appear to influence treatment outcomes. Moreover, while FMT can induce clinical remission, mucosal healing an important marker of long-term success is not always achieved, which may limit the long-term benefits of FMT.

Safety and Side Effects

FMT is generally considered safe, but there are concerns about its potential side effects and long-term risks, especially when used in UC patients. The most commonly reported side effects include mild gastrointestinal symptoms such as bloating, cramping, diarrhea, and constipation. In most cases, these symptoms are transient and resolve within a few days following the procedure. In the study by Moayyedi *et al.* (2015) [2], 19% of patients reported mild gastrointestinal symptoms, while in the study by Rossen *et al.* (2015) [4], 23% reported similar issues. However, these symptoms were not significantly different from those in the placebo group.

In rare cases, more serious complications have been reported, including infections and, in one case, a patient developed bacteremia after FMT. To mitigate such risks, strict donor screening protocols are essential. Current guidelines recommend screening donors for infectious diseases, including bacterial, viral, and parasitic infections, as well as conducting a thorough medical history review. Rossen *et al.* (2015) [4] highlighted that in their study, no serious adverse events related to FMT were observed, underscoring the importance of rigorous donor selection.

Long-term data on the safety of FMT is limited, particularly regarding its use in UC. While most studies report that FMT is well tolerated, concerns have been raised about the potential for FMT to induce immune dysregulation or trigger other chronic diseases. Given the central role of the microbiota in regulating immune function, altering the microbial landscape through FMT could have unintended consequences, such as increasing the risk of developing

autoimmune conditions. More research is needed to understand the long-term risks and benefits of FMT in UC patients.

Study	Adverse Events	Infection Rate
Moayyedi *et al.* (2015) [2]	19% mild GI symptoms	0%
Rossen *et al.* (2015) [4]	23% mild GI symptoms	0%
Costello *et al.* (2019) [5]	16% mild GI symptoms	1% (bacteremia)

Given these safety concerns, more robust screening procedures and follow-up care protocols are necessary to ensure patient safety. The development of standardized FMT protocols, including donor screening and administration procedures, will be critical in ensuring the long-term safety and efficacy of this therapy for UC.

Challenges and Future Directions

While FMT has shown potential as a therapeutic option for UC, several challenges remain before it can become a standardized treatment. One of the main challenges is the variability in patient response. Not all patients benefit from FMT, and the reasons for this variability are not fully understood. Factors such as disease severity, duration, and individual microbial profiles likely play a role in determining the success of FMT. Future research should focus on identifying biomarkers that can predict patient response to FMT, allowing for a more personalized approach to treatment.

Donor selection is another critical factor in the success of FMT. As discussed, the microbial diversity of the donor stool is strongly associated with treatment outcomes. However, there is currently no standardized protocol for selecting donors, and donor screening can be time-consuming and expensive. The development of standardized donor selection criteria, as well as the potential use of synthetic microbiota or stool banks, may help to address this challenge.

Another challenge is the lack of standardization in FMT protocols. Studies have used various delivery methods (e.g., colonoscopy, enema, capsules) and dosing regimens, making it difficult to compare results across trials. There is a need for standardized protocols that outline the optimal delivery method, dosage, and frequency of FMT administration in UC patients.

Finally, while FMT has been shown to induce clinical remission in some UC patients, its long-term efficacy remains uncertain. Some patients experience relapse within months of FMT, suggesting that maintenance therapy may be necessary. Future studies should focus on the long-term effects of FMT in UC and explore the potential for combining FMT with other therapies, such as biologics or immunosuppressants, to improve outcomes

Conclusion

Fecal microbiota transplantation (FMT) represents a promising therapeutic option for ulcerative colitis (UC), offering a novel approach to restoring microbial balance in patients with dysbiosis. While multiple studies have demonstrated that FMT can induce clinical remission and improve gut health in UC patients, its efficacy varies depending on the donor, method of administration, frequency of transplantation, and individual patient factors. FMT has been shown to modulate immune responses, enhance the production of short-chain fatty acids (SCFAs), and improve mucosal healing. However, challenges remain in terms of optimizing donor selection, standardizing FMT protocols, and ensuring long-term efficacy. Safety concerns also exist, though the majority of studies suggest that FMT is well-tolerated, with mild and transient side effects. Looking ahead, future research should aim to refine FMT methodologies, develop predictive biomarkers for patient response, and address long-term outcomes. By addressing these challenges, FMT has the potential to become a widely accepted treatment for UC, particularly in patients who do not respond well to conventional therapies.

References

1. Paramsothy S, Kamm MA, Kaakoush NO, *et al*. Multidonor intensive fecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228.
2. Moayyedi P, Surette MG, Kim PT, *et al*. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102-109.
3. Dai Z, Zhang J, Wu Q, Chen J, Liu J, Wang Y. Fecal microbiota transplantation in ulcerative colitis: A systematic review and meta-analysis. Am J Gastroenterol. 2020;115(5):755-763.
4. Rossen NG, Fuentes S, van der Spek MJ, *et al*. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110-118.
5. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota transplant for recurrent *Clostridium* difficult infection using long-term frozen stool is effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 2019;45(3):319-330.
6. Vermeire S, Joossens M, Verbeke K, *et al*. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):387-394